IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4107
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$746M
Keith M. Gottesdiener
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.
Headcount
—
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PRME Prime Medicine, Inc. | 35 | 30 | 41 | 52 | - | - | -128.3% | -53.9% | 100.0% | -9686.2% | -9385.7% | 486.1% | 0.0% | 138.0x | $746M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Prime Medicine, Inc. (PRME) receives a "Avoid" rating with a composite score of 35.0/100. It ranks #4107 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for PRME.
View All RatingsROE proxy -128.3% (sector -1.9%)
GM 100% vs sector 44%, OM -9686% vs sector 3%
Capital turnover N/A, R&D intensity 3319.1%
Rev growth 486%, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Prime Medicine, Inc. (PRME) as Avoid with a composite score of 35.0/100 at a current price of $3.83. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Prime Medicine, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.0/100 places it at rank #4107 in our full universe.
No Moat
Very High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 138% D/E amplifies downside risk.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Prime Medicine, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Prime Medicine, Inc. with an Avoid rating, assigning a composite score of 35.0/100 and 1 out of 5 stars. Ranked #4107 of 7,333 stocks, PRME falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
PRME's quality score of 30/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -128.3% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -9385.7% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, PRME appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 3.65x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Prime Medicine, Inc.'s investment score of 22/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 486.1% vs. a sector average of 6.7% and a return on assets of -53.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PRME demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 486.1% year-over-year, while a beta of 1.90 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
Prime Medicine, Inc. registers a low stability score of 21/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.90 and a debt-to-equity ratio of 138.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Prime Medicine, Inc.'s short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.90), elevated leverage (D/E: 138.00x), small-cap liquidity risk. At $746M (small-cap), PRME carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Prime Medicine, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4107 of 7,333 overall (44th percentile). Key comparisons include ROE of -128.3% trailing the -1.9% sector median and operating margins of -9686.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PRME currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (21) would have the largest impact on the composite score.
ROE 6652% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 386004% BELOW SECTOR MEDIAN
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth has been robust throughout the year, recent divergent data on consumer spending and the labor market have put doubt on future […]
Prime Medicine (NASDAQ:PRME) saw its shares drop 7.9% to $3.97 on Thursday, with trading volume significantly below average. The company faces mixed analyst ratings, ranging from "strong-buy" to "sell," resulting in a "Moderate Buy" consensus from MarketBeat. Financially, Prime Medicine reported weak fundamentals in its latest quarter, including missed EPS estimates, low revenue, and a very negative net margin.
Prime Medicine, Inc. (NASDAQ:PRME) saw its market capitalization increase by US$161 million, following a 28% stock rise that rewarded insiders who bought shares over the last year. These insiders realized a 263% gain on their initial US$283.9k investment. The CEO made a significant purchase, and insiders collectively own 15% of the company, indicating confidence in its future.
Prime Medicine, Inc. (PRME) reported a Q3 loss of $0.32 per share, missing the Zacks Consensus Estimate of $0.28, and revenues of $1.23 million, which also fell short of expectations. Despite the financial misstep, the company's shares have risen 43.2% year-to-date, outperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Prime Medicine, Inc. announced that CEO Allan Reine, M.D., will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The company specializes in developing gene editing therapies using its proprietary Prime Editing platform. A live audio webcast and replay will be available on Prime Medicine’s website.
Above 50MA
37.18%
Net New Highs
+51081